Harpoon Therapeutics, Inc. (HARP)

NASDAQ: HARP · IEX Real-Time Price · USD
0.744
+0.053 (7.75%)
At close: Mar 31, 2023, 4:00 PM
0.760
+0.016 (2.12%)
After-hours: Mar 31, 2023, 7:51 PM EDT
7.75%
Market Cap 27.87M
Revenue (ttm) 31.92M
Net Income (ttm) -67.73M
Shares Out 37.45M
EPS (ttm) -2.04
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 197,513
Open 0.685
Previous Close 0.691
Day's Range 0.685 - 0.750
52-Week Range 0.586 - 5.160
Beta 1.56
Analysts Buy
Price Target 6.95 (+833.89%)
Earnings Date May 11, 2023

About HARP

Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company develops tri-specific T cell activating construct (TriTAC) product candidate, including HPN328, which is in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors; HPN217 that is in Phase I/II cl... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Feb 8, 2019
Employees 86
Stock Exchange NASDAQ
Ticker Symbol HARP
Full Company Profile

Financial Performance

In 2022, HARP's revenue was $31.92 million, an increase of 34.92% compared to the previous year's $23.65 million. Losses were -$67.73 million, -41.97% less than in 2021.

Financial Statements

Analyst Forecast

According to 14 analysts, the average rating for HARP stock is "Buy." The 12-month stock price forecast is $6.95, which is an increase of 833.89% from the latest price.

Price Target
$6.95
(833.89% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Harpoon Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

HPN217 (BCMA) and HPN328 (DLL3) enrollment on track, with data updates and selection of recommended Phase 2 doses for both active clinical programs planned in 2023

4 days ago - GlobeNewsWire

Harpoon Therapeutics Announces Closing of $25 Million Private Placement

SOUTH SAN FRANCISCO, Calif., March 27, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP) (the “Company”), a clinical-stage immuno-oncology company developing novel T cell engagers, to...

4 days ago - GlobeNewsWire

Harpoon Therapeutics Announces Acceptance of Five Abstracts for Presentation at AACR Annual Meeting 2023

SOUTH SAN FRANCISCO, Calif., March 14, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immuno-oncology company developing novel T cell engagers, today announced th...

2 weeks ago - GlobeNewsWire

Harpoon Therapeutics to Participate in the SVB Securities Global Biopharma Conference

SOUTH SAN FRANCISCO, Calif., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immuno-oncology company developing novel T cell engagers, today announced tha...

1 month ago - GlobeNewsWire

The 3 Most Undervalued Penny Stocks to Buy in February 2023

If finding undervalued stocks is good, then finding undervalued penny stocks is even better. That's because, with penny stocks, investors' capital appreciation upside potential is amplified.

Other symbols: KGCUEC
2 months ago - InvestorPlace

New Strong Buy Stocks for January 27th

GWRS, EVBG, SPLK, RELL and HARP have been added to the Zacks Rank #1 (Strong Buy) List on January 27, 2023.

Other symbols: EVBGGWRSRELLSPLK
2 months ago - Zacks Investment Research

Why Fast-paced Mover Harpoon Therapeutics, Inc. (HARP) Is a Great Choice for Value Investors

If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Harpoon Therapeutics, Inc. (HARP) could be a great choice. It is one of the several ...

2 months ago - Zacks Investment Research

7 Stocks to Add to Your 10x Watchlist

There are few things that get growth investors excited like the opportunity to invest in 10x stocks. By definition, these 10x stocks (also referred to as 10 baggers) can add huge gains to your portfol...

3 months ago - InvestorPlace

Harpoon Therapeutics Remains Volatile After Promising News

Harpoon Therapeutics offers an example of biotech's volatility. The stock advanced as much as 191% intraday Monday before settling down to a gain of 22.61%.

3 months ago - MarketBeat

Three Small-Cap Biotech Stocks to Consider Now

This article looks at three small-cap biotech companies with stock prices that are making significant moves and have a bright outlook for 2023

Other symbols: ABEOHTGM
3 months ago - MarketBeat

Why Is Harpoon Therapeutics (HARP) Stock Up 100%+ Today?

Harpoon Therapeutics (NASDAQ: HARP) stock is taking off on Monday following the release of updated results from its myeloma drug candidate. HPN217 is the company's drug candidate currently undergoing...

3 months ago - InvestorPlace

Harpoon Therapeutics Presents Updated Interim Results at ASH 2022 for Novel T Cell Engager HPN217 in Relapsed/Refractory Multiple Myeloma

SOUTH SAN FRANCISCO, Calif., Dec. 11, 2022 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immuno-oncology company developing novel T cell engagers, today presented upd...

3 months ago - GlobeNewsWire

Harpoon Therapeutics to Host HPN217 Interim Results and Corporate Update Call and Webcast on December 12, 2022

SOUTH SAN FRANCISCO, Calif., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced that ...

4 months ago - GlobeNewsWire

Harpoon Therapeutics to Participate in the Piper Sandler 34th Annual Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced that ...

4 months ago - GlobeNewsWire

Harpoon Therapeutics, Inc. (HARP) Reports Q3 Loss, Tops Revenue Estimates

Harpoon Therapeutics, Inc. (HARP) delivered earnings and revenue surprises of 41.67% and 73.11%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for th...

4 months ago - Zacks Investment Research

Harpoon Therapeutics Updates Strategic Priorities and Reports Third Quarter 2022 Financial Results

HPN217 (BCMA) interim data update at ASH 2022; HPN328 (DLL3) exploring dosing regimens and HPN601 (EpCAM) expected to enter the clinic in 2023

4 months ago - GlobeNewsWire

Harpoon Therapeutics to Present Interim Results from Phase 1 Clinical Trial of T Cell Engager HPN217 at the 64th ASH Annual Meeting and Exposition

Updated interim results from Phase 1 clinical trial of HPN217 in heavily pretreated patients with relapsed/refractory multiple myeloma to be presented in a poster at ASH on Sunday, December 11, 2022, ...

5 months ago - GlobeNewsWire

Harpoon Therapeutics Appoints Luke Walker, M.D., as Chief Medical Officer

Harpoon adds experienced drug developer to leadership team Harpoon adds experienced drug developer to leadership team

6 months ago - GlobeNewsWire

Harpoon Therapeutics Appoints Lauren Silvernail to Board of Directors

Industry veteran Lauren Silvernail brings over 30 years of experience in financial leadership roles at life science and related companies Industry veteran Lauren Silvernail brings over 30 years of exp...

6 months ago - GlobeNewsWire

Harpoon Therapeutics to Participate in Three Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced that...

7 months ago - GlobeNewsWire

Harpoon Therapeutics, Inc. (HARP) Reports Q2 Loss, Misses Revenue Estimates

Harpoon Therapeutics, Inc. (HARP) delivered earnings and revenue surprises of 3.64% and 9.95%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock...

8 months ago - Zacks Investment Research

Harpoon Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Presented encouraging interim data for anti-DLL3 T cell engager HPN328 from ongoing dose escalation clinical trial at the 2022 ASCO Annual Meeting

8 months ago - GlobeNewsWire

Harpoon Therapeutics to Participate in Two Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced that ...

8 months ago - GlobeNewsWire

Harpoon Therapeutics Expands Leadership Team

SOUTH SAN FRANCISCO, Calif., July 06, 2022 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced the a...

9 months ago - GlobeNewsWire

Harpoon Presents Interim Data from Ongoing Dose Escalation Portion of T Cell Engager HPN328 Clinical Trial at 2022 ASCO Annual Meeting

SOUTH SAN FRANCISCO, Calif., May 26, 2022 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced interi...

11 months ago - GlobeNewsWire